Cargando…

Anti-Xa activity after subcutaneous administration of dalteparin in intensive care unit patients with and without subcutaneous oedema

Detalles Bibliográficos
Autores principales:	Rommers, M, van der Lely, N, Egberts, T, van den Bemt, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098490/ http://dx.doi.org/10.1186/cc3403

Ejemplares similares

Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study
por: Rommers, Mirjam K, et al.
Publicado: (2006)

A Case of Progressive Subcutaneous Œdema
por: Greig, D. M.
Publicado: (1916)

Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients
por: van der Heijden, Charlotte D. C. C., et al.
Publicado: (2022)

Anti-Xa activities following 5,000 IU and 7,500 IU of s.c. dalteparin in critically ill patients and 5,000 IU in medical patients: a prospective randomized study
por: Heinz, GH, et al.
Publicado: (2013)

Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers
por: Gadiko, C., et al.
Publicado: (2013)

Accuracy of a subcutaneous continuous glucose monitor compared with an intravenous continuous glucose monitor in an intensive care unit
por: Takahashi, Y, et al.
Publicado: (2015)

Whole-body MRI revealed generalized subcutaneous oedema in a patient with juvenile dermatomyositis
por: Fujita, Yuji, et al.
Publicado: (2023)

Subcutaneous vaccine administration – an outmoded practice
por: Cook, Ian F.
Publicado: (2020)

Intolerance in oral versus subcutaneous administration of methotrexate in patients with juvenile idiopathic arthritis: a cross-sectional, observational study
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
por: den Broeder, Alfons A, et al.
Publicado: (2013)

Subcutaneous glucose monitoring in patients with severe sepsis
por: Mader, JK, et al.
Publicado: (2007)

Pyridoxine induced neuropathy by subcutaneous administration in dogs
por: Chung, Jin-Young, et al.
Publicado: (2008)

Minimization of administration route errors with subcutaneous rituximab
por: Liptrott, Sarah, et al.
Publicado: (2016)

Treatment of Phthisis by Subcutaneous Administration of Carbolic Acid
Publicado: (1886)

Does dalteparin PROTECT better than heparin?
por: Przybysz, Thomas, et al.
Publicado: (2011)

P196 A rare presentation of subcutaneous Entomophthoramycosis
por: George, Nimmy Elizabeth, et al.
Publicado: (2022)

Subcutaneous Emphysema From Bronchocavitary Subcutaneous Fistula
por: Shankar, P. S.
Publicado: (2008)

Extensive subcutaneous emphysema treated with subcutaneous angiocatheters
por: Carleton, Lena, et al.
Publicado: (2023)

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
por: Bittner, Beate, et al.
Publicado: (2018)

Ustekinumab pharmacokinetics after subcutaneous administration in swine model
por: Grabowski, Tomasz, et al.
Publicado: (2021)

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
por: Epstein, Robert S
Publicado: (2021)

Lipodystrophy: Still an underdiagnosed complication of subcutaneous insulin administration
por: Barbosa, Mariana, et al.
Publicado: (2022)

Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines
por: Boerrigter, Guido, et al.
Publicado: (2011)

P201 Medicopsis romeroi: an emerging cause of subcutaneous infections
por: Gudisa, Rajendra, et al.
Publicado: (2022)

Critically ill patients with edema and ascites may experience subtherapeutic anti-factor Xa levels following abdominal subcutaneous enoxaparin treatment
por: Tharanon, Vichapat, et al.
Publicado: (2022)

Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit
por: Vlot, E.A., et al.
Publicado: (2020)

Management of venous thromboembolism in patients with cancer: role of dalteparin
por: Linkins, Lori-Ann
Publicado: (2008)

Dalteparin-sodium: Chest wall haematoma: case report
Publicado: (2022)

Management of extensive subcutaneous emphysema with a subcutaneous drain
por: O'Reilly, Peter, et al.
Publicado: (2013)

Subcutaneous Hematoma following Subcutaneous Emphysema: An Occult Association
por: Khandelwal, Ankur, et al.
Publicado: (2017)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
por: Kurtin, Sandra, et al.
Publicado: (2012)

Toxicity Study of Streptococcus pneumoniae Vaccine Administrated Subcutaneously in Rats
por: Park, Sin Jeong, et al.
Publicado: (2011)

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses
por: Martin, Jasmine R., et al.
Publicado: (2015)

Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration
por: Galecio, Juan Sebastián, et al.
Publicado: (2020)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Use of dexmedetomidine repeated subcutaneous administration for balanced anaesthesia in horses
por: Rabbogliatti, Vanessa, et al.
Publicado: (2022)

Subcutaneous REGEN-COV antibody administration in a community pharmacy
por: Dougherty, Tyler S., et al.
Publicado: (2023)

Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration
por: Fadel, Charbel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1p2i6fvrcchsfbc8lrmm0sfkf1